"In this new PNAS study, we investigated 20 women between the ages of 18 and 35 who had developed HA," said Mantzoros.
"These are young, mostly college-age women, mainly runners. They watch their diets, they are slim and appear healthy. But they have abnormal hormone levels, they have ceased menstruating and stopped ovulating and they also have low bone density measures," he added.
Over a period of 36 weeks, the study subjects were given either a synthetic form of leptin (known as metreleptin) or a placebo.
The results showed that daily subcutaneous injections of replacement leptin resulted in significantly elevated levels of the hormone within just a month of treatment.
"Seven of 10 women began to menstruate and four of the seven were found to be ovulating," said Mantzoros.
"Compared with the women who received the placebo, the women who received the metreleptin therapy were also found to have an improved hormonal profile and exhibited higher levels of biomarkers indicating new bone formation," he added.
The findings are reported online this week in the Proceedings of the National Academy of Sciences.
Source-ANI